Northwire Canada EditionThursday, July 16, 2026
Sign inSubscribe
Northwire
⌕
CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6% CLCH 1.17 −4.1% DG 0.035 +0.0% SGML 15.86 −6.0% FURY 0.730 −2.7% CG 22.11 −1.9% ARIS 20.18 −1.1% LAF 1.65 +0.0% MKO 10.18 −2.2% NUG 0.330 −1.5% SGN 0.250 −5.7% AVL 7.99 −0.4% ELE 22.14 −2.7% TRX 1.03 −7.2% PTM 1.83 +0.6% OMM 0.050 −9.1% CBG 0.300 −1.6%
Financings

Hemostemix Closes $480,000 Private Placement at $0.12 per Share

By The Northwire Desk — AI Analysis Dec 31, 2025 · 14:39 HEM · 0.085 Hemostemix Inc.
HEM · Price

Executive Summary

  • Hemostemix Inc. closed a non‑brokered private placement raising CDN $480,000 by issuing 4,000,000 common shares at $0.12 per share.
  • Proceeds will be used for general working capital, specifically to advance regulatory, clinical and commercialization initiatives for the ACP‑01 (VesCell) autologous angiogenic cell therapy platform.
  • All issued securities are subject to a statutory hold period and the placement remains pending final acceptance by the TSX Venture Exchange.

Key Details

  • Gross proceeds: CDN $480,000.
  • Shares issued: 4,000,000 common shares.
  • Price per share: $0.12 CAD.
  • Placement type: Non‑brokered private placement (non‑institutional investors).
  • Use of proceeds: General working capital; funding regulatory filings, clinical trial activities, and commercialization efforts for ACP‑01 (VesCell).
  • Statutory hold period: Shares subject to hold in accordance with securities laws and TSXV policies.
  • TSXV acceptance: Placement pending final acceptance by the Toronto Stock Exchange Venture Board.

Notable Quotes

(No direct quotes were provided in the release.)

Read the original news release →

More from Hemostemix Inc.

Jun 26, 2026 · 08:48

Pre-revenue stem cell therapy developer advancing ACP-01 across ischemic indications while navigating severe liquidity constraints and ongoing dilutive financings.

Financings Jun 17, 2026 · 17:23

Micro-cap Biotech Cuts Financing Price in Half Amid Restatement and Going Concern Warnings

Financings Feb 03, 2026 · 08:56

Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships

Management Jan 16, 2026 · 16:06

Hemostemix gets FDA support for basket protocol

Regulatory Jan 16, 2026 · 12:27

Hemostemix Receives FDA Support for Its Basket Protocol Approach

Regulatory Dec 31, 2025 · 18:13

Hemostemix closes $480,000 financing

Financings